DataCiterelevance policy v2
The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis
DataCiterelevance policy v2
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
DataCiterelevance policy v2
BindingDB Entry 50012323: The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
DataCiterelevance policy v2
Exclusive copyright, patent, know-how, process and technology license to use the 'Sativex' trademarks and trade names to use, import, offer, sell, have sold, commercialize, market, promote, distribute, import, export, package, label and sublicense a botanical oromucosal spray solution drug product that contains extracts of a chemically and genetically characterized cannabis plant with a ratio of the cannabinoids THC (tetrahydrocannabinol) and CBD (cannabidiol), and its formulation improvements, or backup product, to treat spasticity in multiple sclerosis and cancer pain, and to treat, prevent and diagnose all indications in humans and animals, with licensor to supply products.
DataCiterelevance policy v2
Efficacy and safety of cannabinoids in the treatment of spasticity in patients with multiple sclerosis: a rapid review
DataCiterelevance policy v2
Cannabisarzneimittel : was Pflegende darüber wissen sollen
DataCiterelevance policy v2
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
DataCiterelevance policy v2
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy
DataCiterelevance policy v2
Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy
DataCiterelevance policy v2
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis
DataCiterelevance policy v2
BindingDB Entry 50047320: Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.
DataCiterelevance policy v2
Research Appendix to "Chronic Endocannabinoid Deficiency as the Root Cause of Aging and Death by Natural Causes": 360 Cannabis-Related Studies Supporting the ECS Model
DataCiterelevance policy v2
Cannabinoids in multiple sclerosis: efficacy, safety and tolerability
DataCiterelevance policy v2
Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis
DataCiterelevance policy v2
Collaborative development with exclusive patent, know-how and process license to use the 'Sativex,' 'Nabidiolex' and 'Tetranabinex' trademarks and trade names to develop, make, have made, use, sell, import, exploit and sublicense a pharmaceutical product that is an oromucosal spray containing tetrahydrocannabinol from 'Tetrabinex' and Cannabis sativa, and cannabidiol, including formulation improvements, and other products containing a ratio of CBD and THC drug substances, to treat, diagnose, prevent and palliate advanced and early stage cancer pain, neuropathic and other pain, and other diseases, conditions, syndromes and maladies in humans and animals, including multiple sclerosis.
DataCiterelevance policy v2
Selective Endocannabinoid Reuptake Inhibitor WOBE437 Reduces Disease Progression in a Mouse Model of Multiple Sclerosis
DataCiterelevance policy v2
The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis
DataCiterelevance policy v2
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
DataCiterelevance policy v2
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis
DataCiterelevance policy v2
Chronic Endocannabinoid Deficiency as the Root Cause of Aging and Death by Natural Causes — A Systems Model Approach as a Means to Reach Longevity Escape Velocity